ArticleJournal of the American Heart Association2023
Association Between Hypertension and Diabetes Control and COVID-19 Severity: National Patient-Centered Clinical Research Network, United States, March 2020 to February 2022.
Article in Journal of the American Heart Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- A Summary of Cardiometabolic Disorders in the Maghreb: Insights from the 2025 Saclay Cardiometabolic Summit.Cardiology and therapy · 2026Review
- ICU Admission and Post-Discharge Mortality in COVID-19: Different Risk Factors Across Clinical Phases.Medical sciences (Basel, Switzerland) · 2026Observational
- Racial Disparities in Long COVID: Why Black Americans are Likely Underrepresented in Long COVID Estimates.Journal of racial and ethnic health disparities · 2026Review
- Racial and Ethnic Differences in COVID-19 Disease Severity Among US Adults in Health Systems Participating in PCORnet®: May 2020-October 2022.Medical care · 2026Article
- Prevalence of Diabetes Mellitus and Hypertension Among COVID-19 Patients: A Cross-Sectional Study Exploring Associations With Sociodemographic and Biological Factors in Rajshahi Division, Bangladesh.Health science reports · 2025Article
- Coronavirus Disease 2019 Vaccination Booster Effectiveness Based on the 2022 Japanese Dialysis Registry.Nephrology (Carlton, Vic.) · 2025Article
- Assessment of the factors affecting the clinical outcomes of infection and safety of vaccines against SARS-CoV-2 among Egyptian patients.BMC infectious diseases · 2025Article
- Long COVID facts and findings: a large-scale online survey in 74,075 Chinese participants.The Lancet regional health. Western Pacific · 2024Article
- Association between renin-angiotensin antagonism and COVID-19-related mortality in patients with essential hypertension: A single center, retrospective cohort study.Journal of clinical hypertension (Greenwich, Conn.) · 2024Article
- Public Health Surveillance in Electronic Health Records: Lessons From PCORnet.Preventing chronic disease · 2024Article
- Evaluation of blood pressure variation in recovered COVID-19 patients at one-year follow-up: a retrospective cohort study.BMC cardiovascular disorders · 2024Article
- Clinical Outcomes of COVID-19 Infection among Patients with Chronic Obstructive Pulmonary Disease: Findings from the Philippine CORONA Study.Clinics and practice · 2023Article
- Sex differences in patients with COVID-19 after bariatric surgery: a multicenter cross-sectional study.Frontiers in public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Hypertension and diabetes are associated with increased COVID-19 severity. The association between level of control of these conditions and COVID-19 severity is less well understood. Methods and Results This retrospective cohort study identified adults with COVID-19, March 2020 to February 2022, in 43 US health systems in the National Patient-Centered Clinical Research Network. Hypertension control was categorized as blood pressure (BP) <130/80, 130 to 139/80 to 89, 140 to 159/90 to 99, or ≥160/100 mm Hg, and diabetes control as glycated hemoglobin <7%, 7% to <9%, ≥9%. Adjusted, pooled logistic regression assessed associations between hypertension and diabetes control and severe COVID-19 outcomes. Among 1 494 837 adults with COVID-19, 43% had hypertension and 12% had diabetes. Among patients with hypertension, the highest baseline BP was associated with greater odds of hospitalization (adjusted odds ratio [aOR], 1.30 [95% CI, 1.23-1.37] for BP ≥160/100 versus BP <130/80), critical care (aOR, 1.30 [95% CI, 1.21-1.40]), and mechanical ventilation (aOR, 1.32 [95% CI, 1.17-1.50]) but not mortality (aOR, 1.08 [95% CI, 0.98-1.12]). Among patients with diabetes, the highest glycated hemoglobin was associated with greater odds of hospitalization (aOR, 1.61 [95% CI, 1.47-1.76] for glycated hemoglobin ≥9% versus <7%), critical care (aOR, 1.42 [95% CI, 1.31-1.54]), mechanical ventilation (aOR, 1.12 [95% CI, 1.02-1.23]), and mortality (aOR, 1.18 [95% CI, 1.09-1.27]). Black and Hispanic adults were more likely than White adults to experience severe COVID-19 outcomes, independent of comorbidity score and control of hypertension or diabetes. Conclusions Among 1.5 million patients with COVID-19, higher BP and glycated hemoglobin were associated with more severe COVID-19 outcomes. Findings suggest that adults with poorest control of hypertension or diabetes might benefit from efforts to prevent and initiate early treatment of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.